Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-08-13 09:23:58 UTC |
---|
Update Date | 2022-03-07 02:49:20 UTC |
---|
HMDB ID | HMDB0004031 |
---|
Secondary Accession Numbers | - HMDB0013594
- HMDB04031
- HMDB13594
|
---|
Metabolite Identification |
---|
Common Name | 11beta-Hydroxyprogesterone |
---|
Description | 11beta-Hydroxyprogesterone is a normal human metabolite. Plasma 11beta-Hydroxyprogesterone concentrations does not vary significantly as a function of age, sex, or phase of the menstrual cycle, in contrast to 17-hydroxyprogesterone. Increased plasma 11beta-Hydroxyprogesterone levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway. 21-hydroxylase deficiency (OMIM 201910 ) is probably the most frequent (if not the most frequent) autosomal recessive genetic disease, occurring in almost 1% of Caucasians and about 3% of Ashkenazi Jews. 21-hydroxylase deficiency is unusual among genetic diseases in that approximately 95% of the mutant alleles have apparently been generated by recombination between a normally active gene (CYP21) and a closely linked pseudogene (CYP21P). There are 4 recognized clinical forms of congenital adrenal hyperplasia, the majority of cases being associated with 21-hydroxylase deficiency: salt-wasting (SW), simple virilizing (SV), nonclassic (NC) late-onset (also called attenuated and acquired), and cryptic. (PMID: 3546944 , 2537337 ). 11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.It activates the transiently expressed hMR in COS-7 cells in a dose-dependent manner (ED(50): 10(-8) M) and, like aldosterone, stimulated Ams I(sc) in mpkCCD(cl4) cells. Docking 11OHP within the hMR-ligand-binding domain homology model revealed that the agonist activity of 11OHP is caused by contacts between its 11 beta-hydroxyl group and Asn770. Furthermore, 11OHP was unable to activate the mutant hMR/N770A, in which Ala is substituted for Asn at position 770. These findings demonstrate that in the absence of the 21-hydroxyl group, the 11 beta-hydroxyl group can produce the contact with the hMR-Asn770 required for the hMR activation leading to stimulated Na(+) absorption. |
---|
Structure | [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17-,18-,19+,20-,21+/m0/s1 |
---|
Synonyms | Value | Source |
---|
(11beta)-11-Hydroxypregn-4-ene-3,20-dione | ChEBI | 21-Deoxycorticosterone | ChEBI | (11b)-11-Hydroxypregn-4-ene-3,20-dione | Generator | (11Β)-11-hydroxypregn-4-ene-3,20-dione | Generator | 11b-Hydroxyprogesterone | Generator | 11Β-hydroxyprogesterone | Generator | Pregn-4-ene-11 beta-ol-3,20-dione | MeSH | Hylutin | MeSH | Hyprogest | MeSH | 11-Hydroxyprogesterone, (11alpha,17alpha)-(+-)-isomer | MeSH | 11-Hydroxyprogesterone | MeSH | Duralutin | MeSH | Prodrox | MeSH | 11 beta-Hydroxy-4-pregnen-3,20-dione | MeSH | 11-Hydroxyprogesterone, (11beta)-isomer | MeSH | 11-Hydroxyprogesterone, (11alpha)-(+-)-isomer | MeSH | 11-Hydroxyprogesterone, (9beta,10alpha,11alpha)-isomer | MeSH | 11 alpha-Hydroxyprogesterone | MeSH | 11ohp Compound | MeSH | Hy-gestrone | MeSH | Pergestron | MeSH | Pro-depo | MeSH | Gesterol | MeSH | 11-Hydroxyprogesterone, (11alpha)-isomer | MeSH | 11beta-Hydroxy-4-pregnene-3,20-dione | HMDB | 11beta-Hydroxy-P4 | HMDB | 11beta-Hydroxyprogesterone | HMDB | 11β-Hydroxy-4-pregnene-3,20-dione | HMDB | 11β-Hydroxy-P4 | HMDB | Pregn-4-en-11beta-ol-3,20-dione | HMDB | Pregn-4-en-11β-ol-3,20-dione | HMDB | Pregn-4-ene-11beta-ol-3,20-dione | HMDB | Pregn-4-ene-11β-ol-3,20-dione | HMDB | delta4-Pregnene-11beta-ol-3,20-dione | HMDB | Δ4-Pregnene-11β-ol-3,20-dione | HMDB |
|
---|
Chemical Formula | C21H30O3 |
---|
Average Molecular Weight | 330.4611 |
---|
Monoisotopic Molecular Weight | 330.219494826 |
---|
IUPAC Name | (1S,2R,10S,11S,14S,15S,17S)-14-acetyl-17-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
---|
Traditional Name | (1S,2R,10S,11S,14S,15S,17S)-14-acetyl-17-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one |
---|
CAS Registry Number | 600-57-7 |
---|
SMILES | [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17-,18-,19+,20-,21+/m0/s1 |
---|
InChI Key | BFZHCUBIASXHPK-ATWVFEABSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Pregnane steroids |
---|
Direct Parent | Gluco/mineralocorticoids, progestogins and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Progestogin-skeleton
- 20-oxosteroid
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- 11-hydroxysteroid
- 11-beta-hydroxysteroid
- Hydroxysteroid
- Oxosteroid
- Delta-4-steroid
- Cyclohexenone
- Cyclic alcohol
- Ketone
- Secondary alcohol
- Cyclic ketone
- Hydrocarbon derivative
- Organic oxygen compound
- Carbonyl group
- Alcohol
- Organic oxide
- Organooxygen compound
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | - 11beta-hydroxy steroid (CHEBI:28247 )
- C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030168 )
|
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | MetCCS_train_pos | 182.315 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
11beta-Hydroxyprogesterone,1TMS,isomer #1 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3023.9 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,1TMS,isomer #2 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3074.9 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,1TMS,isomer #3 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 2937.1 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,1TMS,isomer #4 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3049.1 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3005.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2898.4 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3264.2 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #2 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2855.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #2 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2881.1 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #2 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3276.4 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #3 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2954.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #3 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2866.3 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #3 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3357.6 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #4 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 2977.6 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #4 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 2984.7 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #4 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3273.5 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #5 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 2936.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #5 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 2962.2 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TMS,isomer #5 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3358.5 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,3TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2871.6 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2942.9 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TMS,isomer #1 | CC(O[Si](C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3244.1 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,3TMS,isomer #2 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2857.0 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TMS,isomer #2 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 2915.3 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TMS,isomer #2 | C=C(O[Si](C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C)C[C@]12C | 3319.5 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,1TBDMS,isomer #1 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3259.3 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,1TBDMS,isomer #2 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3311.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,1TBDMS,isomer #3 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3185.6 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,1TBDMS,isomer #4 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3276.1 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3480.5 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3409.2 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3501.9 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #2 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3309.6 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #2 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3340.5 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #2 | CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3502.0 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #3 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3416.0 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #3 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3373.1 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #3 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3566.8 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #4 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3455.1 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #4 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3407.2 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #4 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3512.3 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #5 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3386.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #5 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3383.7 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,2TBDMS,isomer #5 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C | 3572.7 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,3TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3506.3 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3556.0 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TBDMS,isomer #1 | CC(O[Si](C)(C)C(C)(C)C)=C1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3525.8 | Standard polar | 33892256 | 11beta-Hydroxyprogesterone,3TBDMS,isomer #2 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3488.4 | Semi standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TBDMS,isomer #2 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3528.7 | Standard non polar | 33892256 | 11beta-Hydroxyprogesterone,3TBDMS,isomer #2 | C=C(O[Si](C)(C)C(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]12C | 3567.4 | Standard polar | 33892256 |
|
---|
General References | - Holtta-Vuori M, Maatta J, Ullrich O, Kuismanen E, Ikonen E: Mobilization of late-endosomal cholesterol is inhibited by Rab guanine nucleotide dissociation inhibitor. Curr Biol. 2000 Jan 27;10(2):95-8. [PubMed:10662671 ]
- Herrero P, Soto PF, Dence CS, Kisrieva-Ware Z, Delano DA, Peterson LR, Gropler RJ: Impact of hormone replacement on myocardial fatty acid metabolism: potential role of estrogen. J Nucl Cardiol. 2005 Sep-Oct;12(5):574-81. [PubMed:16171718 ]
- Laatikainen T, Apter D, Wahlstrom T: Steroids in spermatic and peripheral vein blood in testicular feminization. Fertil Steril. 1980 Nov;34(5):461-4. [PubMed:7439411 ]
- Tuckey RC: Progesterone synthesis by the human placenta. Placenta. 2005 Apr;26(4):273-81. [PubMed:15823613 ]
- Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA: Neurosteroid modulation of GABAA receptors. Prog Neurobiol. 2003 Sep;71(1):67-80. [PubMed:14611869 ]
- Antic T, Perry KT, Harrison K, Zaytsev P, Pins M, Campbell SC, Picken MM: Mixed epithelial and stromal tumor of the kidney and cystic nephroma share overlapping features: reappraisal of 15 lesions. Arch Pathol Lab Med. 2006 Jan;130(1):80-5. [PubMed:16390243 ]
- Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJ: Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol. 1994 Aug;8(8):983-95. [PubMed:7997239 ]
- Barnhill SD, Zhang Z, Madyastha KR: Evaluation of a new biochemical index for the estimation of bone demineralization using artificial intelligence. Contemp Orthop. 1995 Apr;30(4):315-8. [PubMed:10150355 ]
- Saxena BB, Clavio A, Singh M, Rathnam P, Bukharovich EY, Reimers TJ Jr, Saxena A, Perkins S: Effect of immunization with bovine luteinizing hormone receptor on ovarian function in cats. Am J Vet Res. 2003 Mar;64(3):292-8. [PubMed:12661868 ]
- Wiebe JP: Nongenomic actions of steroids on gonadotropin release. Recent Prog Horm Res. 1997;52:71-99; discussion 99-101. [PubMed:9238848 ]
- Celayir S, Ilce Z, Dervisoglu S: The sex hormone receptors in the bladder in childhood - I: preliminary report in male subjects. Eur J Pediatr Surg. 2002 Oct;12(5):312-7. [PubMed:12469257 ]
- Agoulnik IU, Krause WC, Bingman WE 3rd, Rahman HT, Amrikachi M, Ayala GE, Weigel NL: Repressors of androgen and progesterone receptor action. J Biol Chem. 2003 Aug 15;278(33):31136-48. Epub 2003 May 27. [PubMed:12771131 ]
- Beer R, Barnhill SD, Madyastha KR: Comparative study of a biochemical index for the estimation of bone demineralization and dual photon absorptiometry. Contemp Orthop. 1995 Mar;30(3):230-4. [PubMed:10150317 ]
- Pepe GJ, Albrecht ED: Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev. 1995 Oct;16(5):608-48. [PubMed:8529574 ]
- Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle CE, Schultz A, Wehling M: Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis. 2002 Jul;13(5):443-7. [PubMed:12138372 ]
- Rasmussen KM, Kjolhede CL: Prepregnant overweight and obesity diminish the prolactin response to suckling in the first week postpartum. Pediatrics. 2004 May;113(5):e465-71. [PubMed:15121990 ]
- Parikh P, Chan TY, Epstein JI, Argani P: Incidental stromal-predominant mixed epithelial-stromal tumors of the kidney: a mimic of intraparenchymal renal leiomyoma. Arch Pathol Lab Med. 2005 Jul;129(7):910-4. [PubMed:15974815 ]
- Money SR, Muss W, Thelmo WL, Boeckl O, Pimpl W, Kaindl H, Sungler P, Kirwin J, Waclawicek H, Jaffe BM, et al.: Immunocytochemical localization of estrogen and progesterone receptors in human thyroid. Surgery. 1989 Dec;106(6):975-8; discussion 979. [PubMed:2686061 ]
- Karalis K, Goodwin G, Majzoub JA: Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat Med. 1996 May;2(5):556-60. [PubMed:8616715 ]
- Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA: Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med. 2003 Dec;9(12):1533-7. Epub 2003 Nov 9. [PubMed:14608378 ]
- Fiet J, Gueux B, Raux-DeMay MC, Kuttenn F, Vexiau P, Brerault JL, Couillin P, Galons H, Villette JM, Julien R, et al.: Increased plasma 21-deoxycorticosterone (21-DB) levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway. J Clin Endocrinol Metab. 1989 Mar;68(3):542-7. [PubMed:2537337 ]
- Gueux B, Fiet J, Galons H, Bonete R, Villette JM, Vexiau P, Pham-Huu-Trung MT, Raux-Eurin MC, Gourmelen M, Brerault JL, et al.: The measurement of 11 beta-hydroxy-4-pregnene-3,20-dione (21-deoxycorticosterone) by radioimmunoassay in human plasma. J Steroid Biochem. 1987 Jan;26(1):145-50. [PubMed:3546944 ]
|
---|